Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 6 publications
Safety, pharmacokinetics, and efficacy of budigalimab with rovalpituzumab tesirine in patients with small cell lung cancer.
Journal: Cancer treatment and research communications
Published: April 21, 2021
First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma.
Journal: Cancer immunology, immunotherapy : CII
Published: November 02, 2020
Model Informed Dosing Regimen and Phase I Results of the Anti-PD-1 Antibody Budigalimab (ABBV-181).
Journal: Clinical and translational science
Published: April 09, 2020
Effects of long-term cryopreservation on peripheral blood progenitor cells.
Journal: Cytotherapy
Published: August 21, 2012
Immunologic effects of an orally available BRAFV600E inhibitor in BRAF wild-type murine models.
Journal: Journal of immunotherapy (Hagerstown, Md. : 1997)
Published: June 28, 2012
Showing 1-6 of 6
Last Updated: 09/26/2026